What you believe and what you value as an organization matters. Discover the DNA of our firm.
Get to know our teams and the stories of select staff members who share why they choose to work at Sands Capital.
Read about some of the latest events, partnerships, and business highlights from Sands Capital.
From aquaculture to semiconductors, European firms are quietly becoming global leaders in innovation, sustainability, and value creation.
In this episode of What Matters Most, Sands Capital Portfolio Manager and Sr. Research Analyst Danielle Menichella discusses the business’ journey from Taser maker to artificial intelligence-powered software developer.
Executive Managing Director and Senior Portfolio Manager Brian Christiansen discusses the importance of candor, collaboration, and entrepreneurialism in creating a culture that promotes long-term thinking.
FPT has harnessed education to drive Vietnam’s digital transformation and human-capital development.
Our philosophy is rooted in the belief that, over time, stock prices will reflect the earnings power and growth of the underlying businesses.
Our latest annual report offers a comprehensive view of how we add value through active stewardship.
Our newest strategy takes an unconstrained approach to seeking the best growth businesses outside of the U.S.
Sands Capital invests in innovative businesses across all stages of the growth spectrum
Director of Technical Research
2022
Farcast Biosciences (2017-2020)
Bangalore, India | Director R&D, Intellectual Property
General Electric (2010 - 2017)
Bangalore, India | Lead Intellectual Property Professional
Brigham & Women’s Hospital, Harvard-MIT Division of Health Science and Technology (2007 - 2010)
Cambridge, MA | Post-doctoral fellow
Indian Institute of Science (2007)
PhD | Organic Chemistry
Indian Institute of Science (2002)
MS | Chemical Sciences
Padmaparna is a director of technical research on the Life Sciences Pulse strategy. She joined Sands Capital in 2022. Before joining the firm, Padmaparna spent 12 years in large multinational and start-up companies, working across life sciences tools and diagnostic programs. She has led the creation of patent portfolios and performed technology and intellectual property analysis to identify research and development and inorganic growth opportunities. Padmaparna received a PhD in bioorganic chemistry from the Indian Institute of Science and completed her postdoctoral research at Harvard Medical School/Brigham and Women’s Hospital, concentrating in targeted drug delivery in cancer.
Notice for non-US Investors